In the present study, we analyzed the capacity of CD34+/ CD36-sorted bone marrow cells of myelodysplasia patients (n = 4) to differentiate along the erythroid lineage in the presence of erythropoietin (Epo) and mast cell growth factor (MGF). Two subgroups could be identified. In 6 patients, a normal number of burst-forming units-erythroid (BFU-Es) were cultured from CD34'1CD36-sorted cells. Cells from these patients did have the capacity to differentiate to colony-forming units-erythroid (CFU-Es) progenitors in cell suspension cultures with Epo plus MGF followed by Epo in the culture assay. Moreover, the cells became CD34-/CD36+/glycophorin A (GpA)' after 7 days of culture with Epo plus MGF, a pattern comparable to that of normal progenitors. In contrast, in 8 patients, a different pattern was observed. No BFU-Es or a low number of BFU-Es were cultured from the CD34+/ CD36-sorted cell fraction that was, in most of the cases, incapable of differentiating to CFU-E progenitors.
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YELODYSPLASIA (MDS) is a preleukemic disorder
M affecting the erythroid, myeloid, and megakaryocytic lineages. The disorder is classified according the FrenchAmerican-British (FAB) classification and comprises refractory anemia (RA), RA with ring sideroblasts (RARS), RA with excess of blasts (RAEB), or RAEB in transformation (RAEB-T).' Particularly in RA and RARS, a differentiation block of the erythroid lineage is observed. Several in vitro culture studies with unsorted bone marrow cells from MDS patients have shown that burst-forming unit-erythroid (BFU-E) and colony-forming unit-erythroid (CFU-E) progenitors do not expand in response to erythropoietin (Epo) or Epo plus mast cell growth factor (MGF) and interleukin-3 (IL-3).2-4 In addition, it has been shown that the defect can be detected at a very early stage in the differentiation pathway, ie, in progenitor cells expanding in the blast colony assay, in which the differentiation along the erythroid lineage is most pronouncedly affected.' The cause of the differentiation defect is unknown. Recent investigations have shown that the Evi-1 gene might be activated in MDS, especially in RAEB and RAEB-T.6,' In transfection experiments, it was shown that inappropriate activation of the Evi-1 gene is associated with a disruption of the erythroid and myeloid development. 8 In the normal counterpart, BFU-E and CFU-E colonyforming cells can be distinguished from each other on the basis of differences in in vitro colony growth and antigen expression. BFU-Es emerge from CD34+/CD36-sorted cells, whereas CFU-Es originate from CD34-/CD36+ cells.
Moreover, it has been shown that the transition of the BFU-E to CFU-E can be mimicked in vitro by culturing CD34*/ CD36-cells in suspension with Epo plus MGF, followed by Epo in the colony assay.' These changes were associated with the loss of CD34 antigen and the appearance of the CD36 antigen. These results raise the possibility that dysfunctions observed in MDS might not only be ascribed to defects in early progenitor cells, but may also be caused by a disturbed transition of the BFU-E to CFU-E colony-forming cell. Therefore, CD34+/CD36-and CD34-/CD36+ Flow cytometry of the sorted population showed that, after 7 days of culture with Epo plus MGF, a high proportion of CD34+/CD36-cells persisted, whereas a low proportion of cells became CD34-/CD36+/GpA+. The unresponsiveness is not caused by the used growth factor combination, because the addition of interleukin-3 did not correct the defect. Evil expression was studied in 9 cases to show whether an aberrant Evi-1 expression correlates with a disturbed erythroid development. Evi-1 expression was shown in 4 of 9 cases, whereas 3 of 9 cases did have a disturbed erythroid differentiation. In summary, the resutts show that the defects in the erythroid development in a subpopulation of patients with myelodysplasia is localized at an early stage of the erythroid differentiation and is associated with the persistent expression of the CD34 antigen and, in some cases, with the expression of Evi-1.
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sorted bone marrow cells from MDS patients were cultured in the presence of Epo and MGF and analyzed for the potential to form erythroid colonies and to modulate antigen expression. The results show that, in a subgroup of patients, a disturbed transition is noticed of the BFU-E colony-forming cell that is associated with the persistent expression of CD34 antigen.
MATERIALS AND METHODS

Patients.
Bone marrow cells were obtained from 14 patients with MDS after informed consent was obtained. The patients were classified according FAB criteria as RA (n = l l ) , RARS (n = 2), and RAEB (n = 1). Clinical characteristics are summarized in Table  1 . In addition, bone marrow cells from healthy controls were obtained after informed consent was obtained.
Mononuclear cells (MNCs) were isolated by density gradient centrifugation using Lymphoprep (Nycomed AS, Oslo, Norway). The MNCs were incubated ovemight in RPMI 1640 culture medium (GIBCO Ltd, Paisley, UK) and 10% fetal bovine serum (FBS; Hyclone, Logan, UT) in a plastic culture disk at 37°C in 5% CO, to allow adherence. Nonadherent cells were incubated with a phycoerythrin-labeled anti-CD34 monoclonal antibody son) in CD34'1CD36-and CD34-/CD36' subpopulations. The purity of the sorted cell fraction was greater then 95%. as tested by reanalysis.
CFU-E and BFU-E assays were performed according to Iscove
(1 X IO4) sorted cell fractions were added to I mL of culture medium consisting of I . 1 % methylcellulose (Dow Chemical Co, Midland, MI), 20% heat-inactivated FBS, 10% deionized bovine serum albumin (BSA; Cohn Fraction V; Sigma Chemical Co, St Louis, MO), 0.1 % a-thiogly cero1 (Sigma), and Iscove's modified Dulbecco's medium (Flow Laboratories, Rockville, MD). All cultures were performed in 24-well culture plates (Costar Co, Cambridge, MA) and kept at 37°C in a 5% C 0 2 in an air-humidified atmosphere. CFU-Es were scored on day 7 according to their characteristic morphology and BFU-Es were scored on day 14 using an inverted microscope. In a limited number of experiments, sodium butyrate (Sigma) was used. The concentration used was 0.5 mmol/ L. A higher concentration was toxic for the cells, as shown in tests with the colony assay (data not shown). CD34'/CD36-cells ( I X IO4) were incubated in duplicates in 100 pL Iscove's medium (GIBCO) with 10% FBS with Epo plus MGF. After 7 days, the total cell numbers were reanalyzed regarding the expression of CD34, CD36, CD7 1 (Becton Dickinson), and glycophorin A (GpA; clone 143; CLB, Amsterdam, The Netherlands). In addition, the cells were washed three times in RPMI 1640 medium and used for the in vitro CFU-E colony assay by culturing the cells in the presence of Epo.
The optimal proliferation of erythroid progenitors in the presence of Epo, MGF, and IL-3 was examined for the following concentrations: 1 U/mL recombinant human Epo (Amgen, Oakland, CA), 1 U/mL MGF (specific activity, 1 X IO5 U/mg; Immunex, Seattle, WA), and 10 ng/mL IL-3 (Genetics, Cambridge, MA).
mRNA extraction, reverse transcription (RT), and polymerase chain reaction (PCR). In most experiments, total cellular RNA was isolated by the guanidium isothiocyanatdcesium chloride method. Total cellular RNA (3 Mg) was resuspended in 7 pL diethyl pyrocarbonate (DEPC; Sigma) -treated HZO and incubated at 68°C for IO minutes. After cooling on ice, the samples were spun briefly in a microcentrifuge. Evi-1 and GAPDH primer pairs were synthesized on a Gene Assembler plus DNA synthesizer (Pharmacia) and purified using NAP 10 columns (Pharmacia). One microliter of 50 MmoVL of Evi-l primers or 1 pL of 50 pmol/L GAPDH primers was added to each RT reaction sample and DEPC H20 to a final volume of 50 pL. The samples were heated for 3 minutes at 94°C and spun briefly in a microcentrifuge and placed on ice. Taq DNA polymerase (0.5 p L of 5 U/pL; Pharmacia) was added to each sample. The samples were overlaid with 50 pL paraffin oil. The tubes were placed in a thermal cycler. PCR was performed for 40 cycles: 1 minute of denaturation at 9 4 T , 1 minute of annealing at 6 0 T , and 1 minute of extension at 72°C. The Evi-1 primers used in this study were S'AGCAACGTC-GAATCAAGACCTGCTTCAGAT, bp 21 10-2 139; and S'ACT-GACTGTAAGAGCTCACTGGCCTCAGGT, bp 236 1-2390. For GAPDH, we used a 5' primer AAGGCTGTGGGCAAGGTCAT and a TACTCCITTGGAGGCCATGTG primer spanning a 366-nt fragment. After 40 PCR cycles, I O pL of the reaction mixture was run on a 1.5% agarose gel containing 0.2 pg/L ethidium bromide in I x TRE buffer. A 100-bp ladder (Phannacia) was used as the DNA marker.
To further confirm the identity of the PCR products as Evi-l sequences, both Evi-1 products from the RT-PCR reactions using K562 and RNA from patients were ligated into the Sma I site of pUC-18 (Sure clone ligation kit; Pharmacia). After transformation, clones containing the PCR fragments Cloning of Evi-1 PCR products. Abbreviation: ND, not done. * CD34'/CD36-or CD34-/CD36' cells were cultured in the presence of Epo and MGF. CFU-Es colony number (xlO' cells) and BFU-Es number (xlO' cells) were counted after 7 and 14 days, respectively.
t CD34'/CD36-cells (lO'/lOO ML) were cultured in suspension with Epo plus MGF for 7 days followed by cell-culture assay in the presence of Epo. After 7 days, the CFU-Es were counted. 
RESULTS
Patients' characteristics.
Bone marrow cells were collected from 14 patients with MDS. The clinical characteristics are depicted in Table 1 . In 3 of 13 cases, cytogenetic abnormalities were shown that included 5 q-abnormalities in 2 cases. Five patients received red cell blood transfusions on a regular basis. The other cases were not transfusiondependent.
The effects of Epo plus MGF on MDS progenitors. Bone marrow cells of MDS patients were sorted in CD34'/CD36-and CD34-/CD36' cell fractions and cultured in the colony assay in the presence of Epo plus MGF. In 8 cases, the CD34'/CD36-cells contained low amounts to no BFU-Es (patients no. 1 through 8). whereas CFU-E colony-forming cells did not emerge from this cell fraction. In patients no. 9 through 14, normal BFU-E colony numbers were cultured from the CD34'/CD36-sorted cells compared with the results of normal bone marrow progenitors. CFU-Es could not be shown in any of these 6 patients in the in vitro colony assay. In 6 cases, CD34-/CD36' sorted cells were cultured in the presence of Epo plus MGF. In 1 of 6 cases, CD34-/ CD36' cells contained normal numbers of CFU-Es, whereas in the additional cases, no or a low number of CFU-Es were shown.
To demonstrate whether the BFU-E colony-forming cell can differentiate along the erythroid lineage, cell suspension cultures were performed with CD34'/CD36-sorted cells for 507 7 days in the presence of Epo plus MGF followed by Epo in the colony assay. As shown in Table 2 , a high number (>900) of CFU-Es was cultured in 8 of 14 patients (no. 7 through 14) in the CFU-E assay. In 4 patients (no. 2 through 3 , no CFU-Es were cultured from CD34'/CD36-sorted cells, whereas, in patients no. 1 and 6, a reduced number of CFU-Es was shown.
Experiments were next performed to study whether an aberrant expression of CD34 and CD36 antigen is associated with a disturbed proliferation and/or differentiation of the CD34'/CD36-sorted cells. Sorted MDS cells were cultured For personal use only. on September 24, 2017. by guest www.bloodjournal.org From in suspension with Epo plus MGF and, after 7 days, the antigen profile was studied ( Table 3 and Fig l) . The results were compared with CD34'/CD36-sorted cells from normal bone marrow cultured under the same experimental conditions. Reanalysis of the sorted cell population at day 0 showed a purity of 90% or greater. In patients no. 1 through 8, a population of cells persisted that was characterized by a high proportion of CD34'/CD36-and a low proportion of CD34-/CD36' cells. A subpopulation of the cells showed a partial differentiation reflected by the appearance of CD34'/ CD36' cells. A different pattern was observed in patients no. 9 through 14. Reanalysis of the sorted cell population after 7 days of culture showed a low proportion of CD34'/ CD36-and a high proportion of CD34-/CD36' cells, a pattern comparable with that normal bone marrow progenitor cells (Fig l) . Finally, the antigen profile was studied on CD34 sorted cells after 7 days of culture with regards to the expression of CD36 and GpA. As shown in Table 4 , there is a high degree of similarity in the antigen expression for CD36 and GpA, except in patients no. 2 and 6. In patient A l 2 3 7 l0 11 12 8 13 no. 2, a high proportion of cells developed with the antigen profile of CD34-/CD36-. Additional analysis on the same cell population with the CD71 MoAb showed that 10% of the cells were CD34'/CD7 1 -. 9% were CD34'/CD7 1 ', 1 I % were CD34-/CD7 1-, and 70% were CD34-/CD71'. In patient no. 6, the cells became CD36' without expression of the GpA antigen.
Effects of Epo in combination with MGF and IL-3 or sodium buryrate. Additional experiments were performed with IL-3 in combination with Epo and MGF to exclude the possibility that the lack of proliferation and differentiation was due to insufficient stimulation of MGF. CD34' sorted cells of patients no. 2, 3, and 5 were cultured in the colony assay in the presence of Epo plus MGF and IL-3. Similar results were obtained, as shown in Table 2 For personal use only. on September 24, 2017. by guest www.bloodjournal.org From cells). In addition, FACS analysis was performed after 7 days of suspension culture with Epo plus MGF and IL-3 and compared with the results of Epo plus MGF. In the patients, no change in the percentage of CD36' and GpA+ cells was observed as a result of the addition of IL-3 (data not shown). Finally cell suspension cultures were performed with Na butyrate (0.5 mmol/L) in combination with Epo plus MGF to show whether Na butyrate could induce differentiation. No distinct change was observed with regard to the percentage of CD34+/CD36-and CD34-/CD36+ cells. Differences were observed within a range of 5%. Similar experiments were performed with sorted CD34+ bone marrow cells and showed a high percentage of CD34+/CD36-(56% 2 5%) in the presence of Na butyrate (0.5 mmol/L). In the absence of Na butyrate, 3% ? 3% CD34+/CD36-were observed. In addition, Na butyrate did not enhance the proliferation in the presence of Epo plus MGF (0, 10 BFU-E/104 CD34+ cells).
The expression of Evi-1 was studied in 9 patients (Fig 2) . The W 6 2 cell line was used as the positive control, whereas the HL-60 cell line functioned as a negative control.6 In 3 patients, Evi-1 expression was shown (no. 1, 7, and 8), whereas in patient no. 12, a faint band was observed. All 3 of these patients had a disturbed development of the erythroid lineage. The PCR products of the K562 cell line and patients who had positive results were cloned and sequenced and then compared with the published Evi-1 sequences. The Evi-I sequences of all PCR products were identical with alternate Evi-I RNA tranMoreover, it was shown that Evi-1 expression was present in the erythroid lineage. BFU-Es from patient no. 7 were cultured on large scale in the presence of Epo plus MGF and analyzed for the expression of Evi-I. As shown in Fig  2B, Evi-1 expression could be shown in the erythroid lineage.
Expression of the Evi-1 gene.
scripts. I '
DISCUSSION
In the present study, we analyzed the growth characteristics of CD34+/CD36-and CD34-/CD36+ sorted cell fractions from MDS patients in response to Epo plus MGF stimulation. A distinct difference in growth patterns was observed between the different MDS patients. In 8 cases, a reduced or absent BFU-E colony formation was observed from CD34+/ CD36-sorted cells, whereas in the additional cases, a normal erythroid colony formation was shown. The unresponsiveness to Epo plus MGF could not be ascribed to the growth factor combination because the addition of IL-3 to Epo plus MGF did not correct the reduced erythroid colony formation. The reduced in vitro erythroid colony formation was associated with a disturbed erythroid differentiation. CD34+/CD36-cells cultured in suspension in the presence of Epo plus MGF did not differentiate to CFU-E colonyforming cells. In addition, flow cytometry showed that the CD34 antigen persisted on the sorted cell population during the cell suspension phase or demonstrated a slight erythroid commitment reflected by the appearance of CD34+/CD36+ or CD34+/GpA+ cells. These data are in contrast to normal progenitors that differentiate to CFU-E colony-forming cells in the presence of Epo plus MGF and become CD34-/ CD36+/GpA+. ' The results indicate that, in a subpopulation of MDS patients, a differentiation defect is located in the early stem cell compartment, resulting in an incapability to differentiate along the erythroid lineage.
Recent investigations with cell lines have shown that an aberrant expression of the Evi-1 gene is associated with a differentiation defect along the myeloid and erythroid lineages. Evi-1 gene expression especially occurred in cases with the chromosomal abnormality t (3,3)(q21;q26) or  in~(3,3)(q21-22;q26) .6-~,** However, in cases without chromosomal abnormalities, Evi-1 might also be e~pressed.~.'~ In the present study, we observed that Evi-1 mRNA was expressed in 3 of 9 of the cases. The results are in accordance with findings of Dreyfus et a l . I 3 They observed Evi-1 expression in 1 of 9 patients with RA or RARS, whereas a higher frequency was noticed in patients with RAEB or RAEB-T. Their results suggest that the expression of Evi-1 gene is acquired during the course of the disease. In all cases of the present study, the Evi-1 expression is associated with a disturbed erythroid differentiation.
The persistent expression of CD34 on the progenitor cell population is of interest. Recent studies have shown that different (proto-)oncogenes regulate the expression of CD34. In particular, proteins encoded by the Ets-2 and c-myb genes can bind to the CD34 promoter region, resulting in an enhanced transactivation.14 Moreover, persistent expression of c-myb is associated with a disturbed differentiation of erythroid cell lines. 15 In light of these data, it is conceivable that the persistent expression of CD34 is caused by continuous transactivation of the CD34 promoter as a result of oncogene activation. Whether this is due to c-myb or might be caused by additional oncogenes requires further study. Alternatively, additional defects might have occurred in the regulation of the CD34 gene. Transfection experiments with genes encoding the full-length or truncated CD34 gene have shown that the differentiation program is blocked in cells transfected with the full-length CD34.16 This was not the case in cells transfected with the truncated form, indicating that the type of CD34 transcript is of importance for the differentiation program of hematopoietic cells.
Finally, the results show that transfusion dependency is more frequently associated with a disturbed erythroid differentiation (50% v 16%). However, a larger sample size is required to show the statistical significancy of the observation.
In summary, the data show a disturbed differentiation of erythroid progenitors in a subgroup of MDS patients that is associated with a persistent expression of the CD34 antigen and in some cases in conjunction with expression of Evi-1.
